Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924433 | 0.85 | LMNA (0.60) | DHODHLMNANPSR1PARP1PARP15 | |
| SCHEMBL3918366 | 0.84 | PARP1 (0.61) | DHODHLMNARAB9ANPSR1EPHX2 | |
| SCHEMBL10797563 | 0.82 | LMNA (0.64) | DHODHLMNANPSR1PARP1PARP15 | |
| SCHEMBL3915670 | 0.80 | DHODH (0.81) | DHODHNPC1RAB9ANPSR1PARP1 | |
| SCHEMBL3914856 | 0.80 | DHODH (0.69) | DHODHNPC1RAB9ANPSR1PARP1 | |
| SCHEMBL30913585 | 0.80 | DHODH (0.69) | DHODHLMNANPC1RAB9ANPSR1 | |
| SCHEMBL3914445 | 0.79 | LMNA (0.67) | DHODHLMNARAB9A | |
| SCHEMBL3918240 | 0.78 | LMNA (0.53) | LMNAEPHX2 | |
| SCHEMBL3915266 | 0.78 | DHODH (0.77) | DHODHNPC1RAB9ANPSR1PARP1 | |
| SCHEMBL249112 | 0.78 | DHODH (1.00) | DHODHNPSR1PARP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093214-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-2093214-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-09-07 | — | — | US | disclosed |
| CN-1525954-A | Novel compounds useful as anti-inflammatory, immunomodulatory and antiproliferative agents | 4SC�ɷݹ�˾ | 2004-09-01 | — | — | CN | disclosed |
| EP-1392642-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003006425-A9 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-02-26 | — | — | WO | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006425-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | DHODH 1/4885LMNA 4710/4885NPC1 1461/4885 |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, HADHA | DHODH 1/4885LMNA 4737/4885NPC1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.